Announcement

AbbVie Announces Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie

Financing

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

AbbVie

Clinical Trials

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie

Drug Update

AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.

AbbVie

M&A

AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

AbbVie

Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio

AbbVie

Partnership

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie

M&A

AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan

AbbVie

Business

AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition

AbbVie

Collaboration

AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics

AbbVie

FDA Approval

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis

AbbVie

M&A

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

AbbVie

M&A

AbbVie to Acquire Allergan for $63 Billion

AbbVie